Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.
Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Pausing of AstraZeneca's Coronavirus Study Aids Pfizer, Moderna
by Indrajit Bandyopadhyay
The pause in AstraZeneca's (AZN) voluntary coronavirus study following an adverse event provides its competitors a breather.
3 Safe Blue Chip Stocks to Buy as Market Bounces Back After Tech Selloff
by Benjamin Rains
There could be more selling ahead and the election might cause turbulence. Nonetheless, long-term investors might want to consider adding a few safe blue chip stocks to their portfolios...
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.18, marking a +0.7% move from the previous day.
Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe
by Zacks Equity Research
Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.
Moderna Gets Rating Downgrade, Takes Safety Pledge, Stock Down
by Zacks Equity Research
Moderna (MRNA) pledges with eight other pharma companies to ensure commercialization of a safe and effective vaccine. However, anticipated competitive pressure weighs on the stock.
CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge
by Kinjel Shah
The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.
Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study
by Kinjel Shah
Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.
Coronavirus Vaccine Makers May Make Joint Safety Pledge
by Kinjel Shah
The vaccine developers are likely to pledge to observe high ethical standards in conducting clinical studies and manufacturing of the vaccines, the Wall Street report said.
Pharma Stock Roundup: SNY, GSK, AZN's Coronavirus Vaccines/Treatments Progress
by Kinjel Shah
AstraZeneca (AZN) begins phase III study on COVID-19 vaccine candidate in the United States. Sanofi (SNY)/Glaxo's (GSK) vaccine enters clinical stage.
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.
AstraZeneca's Imfinzi Gets EU Approval for First-Line SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets approval in Europe to treat extensive-stage small cell lung cancer.
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
Novavax to Supply Coronavirus Vaccine to Canadian Government
by Zacks Equity Research
Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Stock Market News for Sep1, 2020
by Zacks Equity Research
U.S. stock markets closed mostly lower on Monday as investors booked profit after a week-long rally.
Lessons for Equity Investors From Dow Jones' Big Shake-Up
by Nilanjan Choudhury
The Dow Jones is a rare example of an index constructed on the basis of a component's share price.
AstraZeneca Begins Coronavirus Vaccine US Phase III Study
by Zacks Equity Research
AstraZeneca's(AZN) phase III study to enroll 30,000 adult participants and assess the safety, efficacy and immunogenicity of its COVID-19 vaccine candidate, AZD1222.
Bull of the Day: Salesforce.com (CRM)
by David Borun
This brand-new Dow component continues to beat the estimates and raise guidance.
Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates
by Kinjel Shah
AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.
Dow Turns Green YTD in Old Format: What Will the Revamp Unfold?
by Nalak Das
The revamp is likely to make the Dow more market-friendly and reflect investors' sentiments more accurately.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH